3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 32026-10-06NCT06084936
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerActive, not recruitingPhase 32026-09-14NCT06065748
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudySolid TumorsActive, not recruitingPhase 22026-09-04NCT04589845